Clinical trials
Phase 1/2 Leukemia, Myeloid, Acute trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 3 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 60 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The First Affiliated Hospital of Soochow University | 4 |
| Chinese PLA General Hospital | 3 |
| Ascentage Pharma Group Inc. | 2 |
| Chongqing Precision Biotech Co., Ltd | 2 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2 |
| The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2 |
| ZePing Zhou | 2 |
| Actinium Pharmaceuticals | 1 |
| Betta Pharmaceuticals Co., Ltd. | 1 |
| BioSight Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 60 |
| Myelodysplastic Syndromes | 18 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Recurrence | 8 |
| Leukemia | 6 |
| Hematologic Neoplasms | 3 |
| Leukemia, Myeloid | 3 |
| Lymphoma | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Anemia, Aplastic | 2 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.